Fig. 2.

BH10 shows improved cancer cell-selective toxicity compared to other anti-cancer quinones and molecules that disrupt glucose metabolism. Non-cancerous MAD11 (blue lines) and cancerous HEC1A cells (red lines) were exposed to increasing doses of (A) BH10, (B) CDC25 phosphatase inhibitor II, (C) vitamin K3, (D) doxorubicin, (E) mitomycin C, (F) β-lapachone, (G) 17-AAG, (H) streptonigrin, (I) dichloroacetate (DCA), and (J) vitamin C, for 48 h. Cell viability is shown as a percentage normalised to vehicle-treated cells. Each compound structure is shown with corresponding graphs. n ≥ 3 for all experiments. Data represent mean ± SEM. Statistical analyses comparing the IC₅₀ values of MAD11 vs HEC1A for each drug are shown in Supp. Table 2. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)